Disposition of DX-52-1, a novel anticancer agent, after intravenous administration to mice and dogs

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 22, Issue 1, 1997, Pages 53-63

  Fuse, E ^a   Nishiie, H ^a   Kobayashi, H ^a   Ikeda, S ^a   Saito, H ^a   Covey, J ^b   Kobayashi, S ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anti cancer drugs; Blood; Distribution; Excretion; Quinocarmycin

Indexed keywords

ANTINEOPLASTIC AGENT; QUINOCARMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BLOOD CELL; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG TISSUE LEVEL; DRUG URINE LEVEL; GALLBLADDER; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; KIDNEY; LUNG; MALE; MOUSE; NONHUMAN; TISSUE DISTRIBUTION;

EID: 0030918173     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03189785     Document Type: Article

References (12)

1. Tomita F.T., Takahashi K., Shimizu K. (1983): DC-52, a novel antitumor antibiotic. I. Taxonomy, fermentation and biological activity. J. Antibiot., 36, 463-467.
2. Takahashi K., Tomita F. (1983): DC-52, a novel antitumor antibiotic. II. Isolation, physico-chemical characteristics and structural determination. J. Antibiot., 36, 468-470.
3. Fujimoto K., Oka T., Morimoto M. (1987): Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152). Cancer Res., 47, 1516-1522.
4. Inoue S., Kubota T., Ohishi T. et al. (1988): Antitumor activity of quinocarmycin citrate (KW-2152) against human tumor xenografts serially transplanted into nude mice. Keio J. Med., 37, 355-364.
5. Jett J.R., Saijo N., Hong W.S. et al. (1987): The colony inhibition of a new therapeutic agent (KW-2152) against human lung cancer cell lines. Invest. New Drugs, 5, 155-159.
6. Inaba S., Shimoyama M. (1988): Antitumor activity of quinocarmycin (KW-2152) against various cultured leukemia and lymphoma cell lines in vitro. Cancer Res., 48, 6029-6032.
7. Plowman J., Dykes D.J., Narayanan V.L. et al. (1995): Efficacy of the quinocarmycins KW-2152 and DX-52-1 against human melanoma lines growing in culture and in mice. Cancer Res., 55, 862-867.
8. Fiebig H.H., Berger D.P., Dengler W.A. et al. (1994): Cyanocyclin A and the quinocarmycin analog NSC 607097 demonstrate selectivity against melanoma xenografts in vitro and in vivo. Proc. Am. Assoc. Cancer Res., 35, 468.
9. Saito H., Hirata T. (1987): Synthetic approach to quinocarcin. Tetrahedron Lett., 28, 4065-4068.
10. Saito H., Kobayashi S., Uosaki Y. et al. (1990): Synthesis and biological evaluation of quinocarcin derivatives. Chem. Pharm. Bull., 38, 1278-1285.
11. Gibaldi M. (1984): Noncompartmental pharmacokinetics. In: Gibaldi M. (Ed.s) Biopharmaceutics and Clinical Pharmacokinetics, 3rd edn. Philadelphia: Lea and Febinger, 17.
12. Boyd M.R. (1989): Status of the NCI preclinical antitumor drug discovery screen. In: DeVita Jr V.T., Hellman S., Rosenberg S.A. (Eds) Cancer: Principles and Practice of Oncology, Updates, Vol 3. Philadelphia: Lippincott, 1-12.